

2014-024 - New potassium channel blockers - extended ShK analogues

Published date: Aug. 16, 2019

Technology description

Researchers from the Monash Institute of Pharmaceutical Sciences and collaborators, have identified novel peptides that are highly potent (low picomolar range) and selective inhibitors of the Kv1.3 potassium channel, an important pharmaceutical target in autoimmune diseases. Clinical support for inhibition of this target with unmodified peptides was achieved in a recent Phase 1b study in patients with active plaque psoriasis. The Monash peptides offer potential clinical and manufacturing advantages due to their high selectivity for Kv1.3 (and not Kv1.1), which reduces off-target side effects and their ability to be developed as recombinant products, which supports GMP scale production.

Institution

[Monash University](#)

联系我们



叶先生

电话：021-65679356

手机：13414935137

邮箱：yeyingsheng@zf-ym.com